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Conclusion
Our aim in writing this book, apart from presenting the ﬁrst history of
fungal diseases, was also to contribute to the historiography of medicine.
In this conclusion, rather than restate and revisit our histories of partic-
ular mycoses, we focus on crosscutting themes concerning the history of
infectious diseases, the limits of the medical gaze, the history of medical
specialisation and biographies of disease.
Our narrative has shown the value of approaching the history of
infection in the twentieth century in terms of ‘seed and soil’. Our read-
ing of the medical record has been against the grain of the common
focus on the ‘seeds’ – the speciﬁc causative organisms – of disease. It is
no surprise that doctors’ histories of infections are in this genre, after
all the major trend in medicine in our period has been to deﬁne dis-
eases in terms of their causes (aetiology), and from the middle of the
century, to treat disease by targeting those speciﬁc causes with drugs,
surgery or other technologies. The history of pulmonary tuberculosis
exempliﬁes this trajectory. First, its medical name changed from phthisis
(wasting) or consumption, a symptomatic deﬁnition, to TB.1 The lat-
ter conﬂated pathology (‘Tuberculosis’) and aetiology (Tubercle bacillus),
and approaching the disease in terms of its ‘seeds’ was reinforced after
1950, when antibiotics arrived as the long sought after ‘magic bullets’
that selectively killed the T. bacillus in the body. Doctors’ histories of
TB tended to write off pre-1950s treatments as ‘unscientiﬁc’ and inef-
fective, as they had focused on making the human ‘soil’ unsuitable for
the T. bacillus, either by strengthening the body through the sanato-
rium regime, or removing the nidus of infection by surgery. Historians
of medicine have been less judgmental and, in recovering the think-
ing and practices of the pre-antibiotic era, have shown the contingent
nature of assessments of scientiﬁcity and efﬁcacy, and suggested that
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for many patients, now abandoned treatments that aimed to improve
bodily ‘soil’ did ‘work’.2
The role of the ‘soil’ in the history of infectious diseases is implicit
in Thomas McKeown’s famous explanation of the decline in mortality
from infectious diseases in Britain in the nineteenth century.3 In his
analysis, he discounted the inﬂuence of factors linked to the ‘seeds’
of infection, such the changing virulence of germs, along with medi-
cal and public health measures targeted at germs, and concluded that
the principal cause of the decline was rising standards of living and
improved nutrition, which had strengthened the body’s soil and resis-
tance to infection. The fact that many people whose body was infected
with a speciﬁc germ did not develop disease was well known to doctors
and especially with TB, as skin tests had long shown that while up to
90% of adults had been infected with the bacillus, only a fraction went
on to develop the disease and fewer died.
In our discussion of fungal infections, we have also extended the
metaphor of the ‘soil’ beyond its normal references to the individual
body and its vulnerability to infection, to an ecological one that also
embraces social and geographical settings, and to how these affected
opportunities for the spread of infection as well as susceptibility. Our
chapter sub-titles refer to particular types of ‘soil’ in this extended
sense. Thus, for ringworm in children the ‘soil’ included an institution –
schools, and for adults with foot infection, the ‘soil’ was a lifestyle –
athleticism. With endemic mycoses, such as coccidioidomycosis, where
the fungi were in fact literally in the soil, our larger notion of ‘soil’
included the social changes that brought in-migration and economic
development. Warwick Anderson has recently highlighted the impor-
tance of the ecological tradition in work on infectious diseases in the
twentieth century, but he shows that this expanded approach remained
nevertheless predominantly ‘biological’, with any social and techno-
logical dimension implicit.4 We have made the latter components
explicit.
This book can be characterised as a history of diseases at the periphery
of the medical gaze, or at the ends of the spectrum of infectious diseases.
At one end, infections such as ringworm and thrush were ubiquitous,
everyday and mostly either self-limited or self-treated, involving at most
a single consultation with a doctor. This is not to deny that such infec-
tions can be chronic and hard to eliminate, even since the arrival of oral
antifungal drugs. At the other end, infections such as candidaemia and
invasive aspergillosis were rare and unusual, sometimes termed ‘orphan
diseases’, and commonly fatal until recent decades.
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But what can a study of these diseases at the margin contribute to
our understanding of the middle, the majority and the mainstream?
Above all, our analysis reminds historians that the minor, self-limiting
and self-treated conditions are common across medicine and not just
with infectious diseases. Illness ‘ice bergs’, the many episodes that do
not reach the medical gaze, were and are present across all areas and
most diseases. Yet, gaze of historians has always tended to be ‘above
the water’. For example, histories of the ‘Great Inﬂuenza Pandemic’ of
1918–1919 emphasise that between 20 and 40 million people died of the
infection or complications such as pneumonia, yet the average mortal-
ity rate was around 2% (varying between 1% and 10%) amongst those
who suffered.5 This rate was very high compared to the normal expe-
rience of inﬂuenza, where case fatality rates was and remains typically
less than 1%.6 Both ﬁgures make our point that the majority patient
experience of inﬂuenza was and is one of recovery; with an illness of
variable severity, which was and is typically self-treated and not require
medical attention, if indeed, the sufferer had access to, or could afford,
professional consultation. Moreover, then, as now, those likely to die of
pneumonia were and are people with underlying health problems; in
other words, those with weakened ‘soil’.
The investigation of rare and unusual diseases highlights the impor-
tance of the adaptation of mainstream ideas and practices to novel
problems, and the opportunities to ‘experiment’ with new methods of
diagnosis and treatment. In an era when standardisation and formal
protocols dominate medical practice, our study of ‘orphan mycoses’ has
shown the variability, complexity and individuality of clinical practice
and the many resources, theoretical, practical and material, that doc-
tors drew upon, and still draw upon, in all aspects of clinical work.
The ways in which uses of amphotericin B, one the earliest antifungal
antibiotic drugs, has been reinvented many times exempliﬁes this adapt-
ability and shows the need to think about invention and innovation as
processes rather than events. The very recognition of ‘orphan diseases’
in part derives from novel medical and social technologies of surveil-
lance, which have provided new types of recognition of infection, such
as X-rays and immune reactions, and new attitudes to risk associated
with social, economic and technological changes, such as the negoti-
ation of thresholds for intervention in public health and with speciﬁc
populations.
Marginality has been studied by historians and sociologists of sci-
ence as a ‘context’ that stimulates innovation.7 These ideas have been
critiqued empirically and for having loose deﬁnitions of marginality
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and innovation, but in this study we have discussed a group – medical
mycologists – who were routinely designated marginal by their profes-
sional peers and saw themselves as such.8 At the end of the twentieth
century, medical mycology remained a small and marginal ﬁeld; indeed,
some in medicine argued that it was often oversold, with specialists
exaggerating the importance of fungal diseases as causes of morbidity
and mortality. We do not want to enter this debate, but instead reﬂect
on the development of medical mycology as a specialism. As we noted
in the Introduction, historical studies of specialisation in medicine are
now less teleological and more nuanced, but there remains a focus on
major specialisms and what might be termed ‘mono-specialists’. As we
have shown, most medical mycologists were ‘multi-specialists’, or had
a number of ‘specialist practices’, even in the United States where the
size of agencies, such as CDC and NIH, or the foci of regionally spe-
ciﬁc infections made mono-specialist careers possible. Indeed, a feature
of our story is that the tension, expected in the 1930s and 1940s,
between ‘botany types’ and ‘medical types’, which can also be seen as
between laboratory and clinic, did not develop.9 Cooperation and col-
laboration were characteristic as roles co-existed and were combined.
In part, this was because of interdependence, especially as clinicians
relied on laboratory-based experts to conﬁrm and reﬁne their diagnoses
and, then after the 1950s, for the development of antifungal antibi-
otics. Solidarity was also prompted by size and marginality, which meant
that creating and maintaining critical mass was a priority and specialist
organisations, not least ISHAM which spanned the Americas and not
just North America, were pivotal in this respect. In the United States,
a presence at NIH and CDC was a boon. In contrast, medical mycolo-
gists in Britain had to be content with a single organisation, the BSMM,
though this effectively lobbied national and, latterly, European agen-
cies. Needless to say, the relatively small size of the ﬁeld meant that
individuals were very important, as too were personal connections and
networks, which were facilitated by air travel from the 1950s, which
made international meetings, both disciplinary and those sponsored by
pharmaceutical companies on single drugs, more common and better
attended. Our focus on diseases has meant that we have not dwelt on the
careers of individual medical mycologists, though the repeated mention
of names of key individuals, often with many infections and in multiple
contexts, is testimony to their success in combining specialist practices.
The biographical mode is now fashionable in the history of medicine,
not only for doctors, scientists and institutions, but diseases too.10 We
have not termed our narratives of fungal infections biographies, but
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have kept with ‘histories’. Roger Cooter, while appreciating the richness
of much of the new biographical genre, has criticised it for tending to
be essentialist and singular, taking diseases as given, rather than look-
ing at their construction and many identities.11 Cooter was after all
making these observations in the Lancet, the implication of his remarks
being that historians of disease need to recognise that ‘modern’, singular
narratives are no longer tenable in ‘the face of contemporary impres-
sions of fragmentation and the collapse of universal meanings’.12 Our
study supports this view. For example, consider the many views put for-
ward on how to explain the rise in the incidence of fungal infections
in the twentieth century. Some doctors maintain the increase was real
and material, some said that it came from new conceptions of what
constituted an infection, others said it was product of new medical
technologies of surveillance and diagnosis, and others that it was iatro-
genic. To these views can be added claims that the apparent rise came
from changing public attitudes to infection and expectations of medical
power. Our conclusion is that all the above forces were in play in the
rise of mycoses, shaping, not just epidemiological patterns, but expe-
riences and meanings; hence, despite the subtitle of this volume, over
the twentieth century, mycoses can be seen as paradigmatic postmodern
diseases.
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